Various treatment strategies, including the use of antibodies targeting CD47, RNA interference for CD47 silencing, and agents modulating CD47 expression, have demonstrated efficacy in cancer treatment by disrupting the interaction between CD47 and SIRPα. This evidence concerns the gene CD47 and cancer.